Design of the Prostate Cancer Prevention Trial (PCPT)

Polly Feigl, Brent Blumenstein, Ian Thompson, John Crowley, Michael Wolf, Barnett S. Kramer, Charles A. Coltman, Otis W. Brawley, Leslie G. Ford

Research output: Contribution to journalArticle

101 Citations (Scopus)

Abstract

The PCPT is a chemoprevention trial of finasteride with a primary endpoint of biopsyproven presence or absence of prostate cancer. A total of 18,000 healthy men, aged 55 years and older, will be randomized. Half will receive finasteride (5 mg/day) and half will receive placebo (one matching tablet per day) for 7 years. The trial is designed to have 92% power to detect a 25% reduction in period prevalence of biopsy-proven disease using a two-sided test with α = 0.05. The trial is complicated by the known impact of finasteride on the major screening test for prostate cancer, prostate specific antigen (PSA). This paper describes the PCPT design with reference to alternatives that were considered. The chosen design depends on five critical assumptions that must be monitored closely throughout the 9-year trial.

Original languageEnglish (US)
Pages (from-to)150-163
Number of pages14
JournalControlled Clinical Trials
Volume16
Issue number3
DOIs
StatePublished - 1995

Fingerprint

Prostatic Neoplasms
Finasteride
Chemoprevention
Prostate-Specific Antigen
Tablets
Placebos
Biopsy

Keywords

  • biased ascertainment
  • Chemoprevention
  • monitoring techniques
  • prostate cancer

ASJC Scopus subject areas

  • Pharmacology

Cite this

Feigl, P., Blumenstein, B., Thompson, I., Crowley, J., Wolf, M., Kramer, B. S., ... Ford, L. G. (1995). Design of the Prostate Cancer Prevention Trial (PCPT). Controlled Clinical Trials, 16(3), 150-163. https://doi.org/10.1016/0197-2456(94)00XXX-M

Design of the Prostate Cancer Prevention Trial (PCPT). / Feigl, Polly; Blumenstein, Brent; Thompson, Ian; Crowley, John; Wolf, Michael; Kramer, Barnett S.; Coltman, Charles A.; Brawley, Otis W.; Ford, Leslie G.

In: Controlled Clinical Trials, Vol. 16, No. 3, 1995, p. 150-163.

Research output: Contribution to journalArticle

Feigl, P, Blumenstein, B, Thompson, I, Crowley, J, Wolf, M, Kramer, BS, Coltman, CA, Brawley, OW & Ford, LG 1995, 'Design of the Prostate Cancer Prevention Trial (PCPT)', Controlled Clinical Trials, vol. 16, no. 3, pp. 150-163. https://doi.org/10.1016/0197-2456(94)00XXX-M
Feigl P, Blumenstein B, Thompson I, Crowley J, Wolf M, Kramer BS et al. Design of the Prostate Cancer Prevention Trial (PCPT). Controlled Clinical Trials. 1995;16(3):150-163. https://doi.org/10.1016/0197-2456(94)00XXX-M
Feigl, Polly ; Blumenstein, Brent ; Thompson, Ian ; Crowley, John ; Wolf, Michael ; Kramer, Barnett S. ; Coltman, Charles A. ; Brawley, Otis W. ; Ford, Leslie G. / Design of the Prostate Cancer Prevention Trial (PCPT). In: Controlled Clinical Trials. 1995 ; Vol. 16, No. 3. pp. 150-163.
@article{bc46c7428e144d568c5f2f5fe58d3dfa,
title = "Design of the Prostate Cancer Prevention Trial (PCPT)",
abstract = "The PCPT is a chemoprevention trial of finasteride with a primary endpoint of biopsyproven presence or absence of prostate cancer. A total of 18,000 healthy men, aged 55 years and older, will be randomized. Half will receive finasteride (5 mg/day) and half will receive placebo (one matching tablet per day) for 7 years. The trial is designed to have 92{\%} power to detect a 25{\%} reduction in period prevalence of biopsy-proven disease using a two-sided test with α = 0.05. The trial is complicated by the known impact of finasteride on the major screening test for prostate cancer, prostate specific antigen (PSA). This paper describes the PCPT design with reference to alternatives that were considered. The chosen design depends on five critical assumptions that must be monitored closely throughout the 9-year trial.",
keywords = "biased ascertainment, Chemoprevention, monitoring techniques, prostate cancer",
author = "Polly Feigl and Brent Blumenstein and Ian Thompson and John Crowley and Michael Wolf and Kramer, {Barnett S.} and Coltman, {Charles A.} and Brawley, {Otis W.} and Ford, {Leslie G.}",
year = "1995",
doi = "10.1016/0197-2456(94)00XXX-M",
language = "English (US)",
volume = "16",
pages = "150--163",
journal = "Controlled Clinical Trials",
issn = "0197-2456",
publisher = "Elsevier BV",
number = "3",

}

TY - JOUR

T1 - Design of the Prostate Cancer Prevention Trial (PCPT)

AU - Feigl, Polly

AU - Blumenstein, Brent

AU - Thompson, Ian

AU - Crowley, John

AU - Wolf, Michael

AU - Kramer, Barnett S.

AU - Coltman, Charles A.

AU - Brawley, Otis W.

AU - Ford, Leslie G.

PY - 1995

Y1 - 1995

N2 - The PCPT is a chemoprevention trial of finasteride with a primary endpoint of biopsyproven presence or absence of prostate cancer. A total of 18,000 healthy men, aged 55 years and older, will be randomized. Half will receive finasteride (5 mg/day) and half will receive placebo (one matching tablet per day) for 7 years. The trial is designed to have 92% power to detect a 25% reduction in period prevalence of biopsy-proven disease using a two-sided test with α = 0.05. The trial is complicated by the known impact of finasteride on the major screening test for prostate cancer, prostate specific antigen (PSA). This paper describes the PCPT design with reference to alternatives that were considered. The chosen design depends on five critical assumptions that must be monitored closely throughout the 9-year trial.

AB - The PCPT is a chemoprevention trial of finasteride with a primary endpoint of biopsyproven presence or absence of prostate cancer. A total of 18,000 healthy men, aged 55 years and older, will be randomized. Half will receive finasteride (5 mg/day) and half will receive placebo (one matching tablet per day) for 7 years. The trial is designed to have 92% power to detect a 25% reduction in period prevalence of biopsy-proven disease using a two-sided test with α = 0.05. The trial is complicated by the known impact of finasteride on the major screening test for prostate cancer, prostate specific antigen (PSA). This paper describes the PCPT design with reference to alternatives that were considered. The chosen design depends on five critical assumptions that must be monitored closely throughout the 9-year trial.

KW - biased ascertainment

KW - Chemoprevention

KW - monitoring techniques

KW - prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=0029311320&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029311320&partnerID=8YFLogxK

U2 - 10.1016/0197-2456(94)00XXX-M

DO - 10.1016/0197-2456(94)00XXX-M

M3 - Article

VL - 16

SP - 150

EP - 163

JO - Controlled Clinical Trials

JF - Controlled Clinical Trials

SN - 0197-2456

IS - 3

ER -